Oncimmune Set For Bigger US Push Of Early-Stage Lung Cancer Test
Executive Summary
Oncimmune Ltd. is seeking new distribution partners in the US as it expands commercialization of its a one-of-a-kind immunoassay for early-stage lung cancer that can detect circulating antibodies in the blood of patients with lung cancer up to four years before standard imaging tests. Positive interim data from a UK randomized clinical trial is expected to help fuel uptake of the test.
You may also be interested in...
Market Intel: Can New Wave Of Tests Finally Nail Early Diagnosis Of Lung Cancer?
Early diagnosis of lung cancer continues to be a major clinical challenge and the opportunity for products that can successfully detect the disease early enough to boost survival rate is huge. This article looks into the market potential and highlights companies developing technologies that they believe can finally turn this deadliest of cancers on its head.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.